Latest Update: Impact of current COVID-19 situation has been considered in this report while making the analysis.
Global Peptide Therapeutics Market by Type (Injection, Oral, Other, The proportion of Injection in 2017 is about 74.2%, and the proportion is decreasing trend from 2013 to 2018.), By Application (Cancer, Metabolic Disorders, Central Nervous System, Other, The key application of peptide therapeutics is into cancer mainly used for treating prostrate, pancreatic, ovarian, and breast cancer. and the consumption proportion is about 33.6% in 2017.) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast To 2028-report

Global Peptide Therapeutics Market by Type (Injection, Oral, Other, The proportion of Injection in 2017 is about 74.2%, and the proportion is decreasing trend from 2013 to 2018.), By Application (Cancer, Metabolic Disorders, Central Nervous System, Other, The key application of peptide therapeutics is into cancer mainly used for treating prostrate, pancreatic, ovarian, and breast cancer. and the consumption proportion is about 33.6% in 2017.) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast To 2028

Report ID: 170900 3300 Pharma & Healthcare 377 248 Pages
                                          

Industry Growth Insights published a new data on “Peptide Therapeutics Market”. The research report is titled “Peptide Therapeutics Market research by Types (Injection, Oral, Other, The proportion of Injection in 2017 is about 74.2%, and the proportion is decreasing trend from 2013 to 2018.), By Applications (Cancer, Metabolic Disorders, Central Nervous System, Other, The key application of peptide therapeutics is into cancer mainly used for treating prostrate, pancreatic, ovarian, and breast cancer. and the consumption proportion is about 33.6% in 2017.), By Players/Companies Sanofi, Eli Lilly, Novo Nordisk, Takeda, Teva, Novartis, AstraZeneca, Ipsen, AbbVie, Allergan, Ferring, Merck, J & J, The Medicines”. As per the latest research Peptide Therapeutics market is expected to expand at a CAGR of xx% in the forecast period.

Scope Of The Report

Report Attributes

Report Details

Report Title

Peptide Therapeutics Market Research Report

By Type

Injection, Oral, Other, The proportion of Injection in 2017 is about 74.2%, and the proportion is decreasing trend from 2013 to 2018.

By Application

Cancer, Metabolic Disorders, Central Nervous System, Other, The key application of peptide therapeutics is into cancer mainly used for treating prostrate, pancreatic, ovarian, and breast cancer. and the consumption proportion is about 33.6% in 2017.

By Companies

Sanofi, Eli Lilly, Novo Nordisk, Takeda, Teva, Novartis, AstraZeneca, Ipsen, AbbVie, Allergan, Ferring, Merck, J & J, The Medicines

Regions Covered

North America, Europe, APAC, Latin America, MEA

Base Year

2020

Historical Year

2018 to 2019 (Data from 2010 can be provided as per availability)

Forecast Year

2028

Number of Pages

248

Number of Tables & Figures

174

Customization Available

Yes, the report can be customized as per your need.


Global Peptide Therapeutics Industry Outlook

Global Peptide Therapeutics Market Report Segments:

The global Peptide Therapeutics market is segmented on the basis of:

Types

Injection, Oral, Other, The proportion of Injection in 2017 is about 74.2%, and the proportion is decreasing trend from 2013 to 2018.

The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.

Applications

Cancer, Metabolic Disorders, Central Nervous System, Other, The key application of peptide therapeutics is into cancer mainly used for treating prostrate, pancreatic, ovarian, and breast cancer. and the consumption proportion is about 33.6% in 2017.

The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.

Some of the companies that are profiled in this report are:

  1. Sanofi
  2. Eli Lilly
  3. Novo Nordisk
  4. Takeda
  5. Teva
  6. Novartis
  7. AstraZeneca
  8. Ipsen
  9. AbbVie
  10. Allergan
  11. Ferring
  12. Merck
  13. J & J
  14. The Medicines

Global Peptide Therapeutics Market Overview

Highlights of The Peptide Therapeutics Market Report:

  1. The market structure and projections for the coming years.
  2. Drivers, restraints, opportunities, and current trends of Alpha Hydroxy Acid for Cosmetic Market.
  3. Historical data and forecast.
  4. Estimations for the forecast period 2028.
  5. Developments and trends in the market.
  6. By Type:

    1. Injection
    2. Oral
    3. Other
    4. The proportion of Injection in 2017 is about 74.2%, and the proportion is decreasing trend from 2013 to 2018.
  1. By Application:

    1. Cancer
    2. Metabolic Disorders
    3. Central Nervous System
    4. Other
    5. The key application of peptide therapeutics is into cancer mainly used for treating prostrate, pancreatic, ovarian, and breast cancer. and the consumption proportion is about 33.6% in 2017.
  1. Market scenario by region, sub-region, and country.
  2. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
  3. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
  4. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Peptide Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2028.

Regional Analysis

  • North America
  • Europe
  • Asia Pacific
  • Middle East & Africa
  • Latin America

Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.

The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.

How you may use our products:

  • Correctly Positioning New Products
  • Market Entry Strategies
  • Business Expansion Strategies
  • Consumer Insights
  • Understanding Competition Scenario
  • Product & Brand Management
  • Channel & Customer Management
  • Identifying Appropriate Advertising Appeals

Global Peptide Therapeutics Market Statistics

8 Reasons to Buy This Report

  1. Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
  2. Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
  3. Implemented Robust Methodology to Prepare the Report
  4. Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
  5. Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
  6. Provides Information About the Top-winning Strategies Implemented by Industry Players.
  7. In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
  8. Customization of the Report Available
                                            
1. Executive Summary

2. Assumptions and Acronyms Used

3. Research Methodology

4. Peptide Therapeutics Market Overview
   4.1. Introduction
      4.1.1. Market Taxonomy
      4.1.2. Market Definition
   4.2. Macro-Economic Factors
      4.2.1. Industry Outlook
   4.3. Peptide Therapeutics Market Dynamics
      4.3.1. Market Drivers
      4.3.2. Market Restraints
      4.3.3. Opportunity
      4.3.4. Market Trends
   4.4. Peptide Therapeutics Market - Supply Chain
   4.5. Global Peptide Therapeutics Market Forecast
      4.5.1. Peptide Therapeutics Market Size (US$ Mn) and Y-o-Y Growth
      4.5.2. Peptide Therapeutics Market Size (000’ Units) and Y-o-Y Growth
      4.5.3. Peptide Therapeutics Market Absolute $ Opportunity

5. Global Peptide Therapeutics Market Analysis and Forecast by Type
   5.1. Market Trends
   5.2. Introduction
      5.2.1. Basis Point Share (BPS) Analysis by Type
      5.2.2. Y-o-Y Growth Projections by Type
   5.3. Peptide Therapeutics Market Size and Volume Forecast by Type
      5.3.1. Injection
      5.3.2. Oral
      5.3.3. Other
      5.3.4. The proportion of Injection in 2017 is about 74.2%, and the proportion is decreasing trend from 2013 to 2018.
   5.4. Absolute $ Opportunity Assessment by Type
   5.5. Market Attractiveness/Growth Potential Analysis by Type

6. Global Peptide Therapeutics Market Analysis and Forecast by Application
   6.1. Market Trends
   6.2. Introduction
      6.2.1. Basis Point Share (BPS) Analysis by Application
      6.2.2. Y-o-Y Growth Projections by Application
   6.3. Peptide Therapeutics Market Size and Volume Forecast by Application
      6.3.1. Cancer
      6.3.2. Metabolic Disorders
      6.3.3. Central Nervous System
      6.3.4. Other
      6.3.5. The key application of peptide therapeutics is into cancer mainly used for treating prostrate, pancreatic, ovarian, and breast cancer. and the consumption proportion is about 33.6% in 2017.
   6.4. Absolute $ Opportunity Assessment by Application
   6.5. Market Attractiveness/Growth Potential Analysis by Application

7. Global Peptide Therapeutics Market Analysis and Forecast by Sales Channel
   7.1. Market Trends
   7.2. Introduction
      7.2.1. Basis Point Share (BPS) Analysis by Sales Channel 
      7.2.2. Y-o-Y Growth Projections by Sales Channel
   7.3. Peptide Therapeutics Market Size and Volume Forecast by Sales Channel 
      7.3.1. Manufacturer/Distributor/Service Provider
      7.3.2. Aftermarket
   7.4. Absolute $ Opportunity Assessment by Sales Channel
   7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel

8. Global Peptide Therapeutics Market Analysis and Forecast by Region
   8.1. Market Trends
   8.2. Introduction
      8.2.1. Basis Point Share (BPS) Analysis by Region
      8.2.2. Y-o-Y Growth Projections by Region
   8.3. Peptide Therapeutics Market Size and Volume Forecast by Region
      8.3.1. North America
      8.3.2. Latin America
      8.3.3. Europe
      8.3.4. Asia Pacific
      8.3.5. Middle East and Africa (MEA)
   8.4. Absolute $ Opportunity Assessment by Region
   8.5. Market Attractiveness/Growth Potential Analysis by Region
   8.6. Global Peptide Therapeutics Demand Share Forecast, 2019-2026

9. North America Peptide Therapeutics Market Analysis and Forecast
   9.1. Introduction
      9.1.1. Basis Point Share (BPS) Analysis by Country
      9.1.2. Y-o-Y Growth Projections by Country
   9.2. North America Peptide Therapeutics Market Size and Volume Forecast by Country
      9.2.1. U.S.
      9.2.2. Canada
   9.3. Absolute $ Opportunity Assessment by Country
   9.4. North America Peptide Therapeutics Market Size and Volume Forecast by Application
      9.4.1. Cancer
      9.4.2. Metabolic Disorders
      9.4.3. Central Nervous System
      9.4.4. Other
      9.4.5. The key application of peptide therapeutics is into cancer mainly used for treating prostrate, pancreatic, ovarian, and breast cancer. and the consumption proportion is about 33.6% in 2017.
   9.5. Basis Point Share (BPS) Analysis by Application
   9.6. Y-o-Y Growth Projections by Application
   9.7. North America Peptide Therapeutics Market Size and Volume Forecast by Type
      9.7.1. Injection
      9.7.2. Oral
      9.7.3. Other
      9.7.4. The proportion of Injection in 2017 is about 74.2%, and the proportion is decreasing trend from 2013 to 2018.
   9.8. Basis Point Share (BPS) Analysis by Type
   9.9. Y-o-Y Growth Projections by Type
   9.10. Market Attractiveness/Growth Potential Analysis
      9.10.1. By Country
      9.10.2. By Product Type
      9.10.3. By Application
      9.10.4. By Sales Channel
   9.11. North America Peptide Therapeutics Demand Share Forecast, 2019-2026

10. Latin America Peptide Therapeutics Market Analysis and Forecast
   10.1. Introduction
      10.1.1. Basis Point Share (BPS) Analysis by Country
      10.1.2. Y-o-Y Growth Projections by Country
      10.1.3. Latin America Average Pricing Analysis
   10.2. Latin America Peptide Therapeutics Market Size and Volume Forecast by Country
      10.2.1. Brazil
      10.2.2. Mexico
      10.2.3. Rest of Latin America
   10.3. Absolute $ Opportunity Assessment by Country
   10.4. Latin America Peptide Therapeutics Market Size and Volume Forecast by Application
      10.4.1. Cancer
      10.4.2. Metabolic Disorders
      10.4.3. Central Nervous System
      10.4.4. Other
      10.4.5. The key application of peptide therapeutics is into cancer mainly used for treating prostrate, pancreatic, ovarian, and breast cancer. and the consumption proportion is about 33.6% in 2017.
   10.5. Basis Point Share (BPS) Analysis by Application
   10.6. Y-o-Y Growth Projections by Application
   10.7. Latin America Peptide Therapeutics Market Size and Volume Forecast by Type
      10.7.1. Injection
      10.7.2. Oral
      10.7.3. Other
      10.7.4. The proportion of Injection in 2017 is about 74.2%, and the proportion is decreasing trend from 2013 to 2018.
   10.8. Basis Point Share (BPS) Analysis by Type
   10.9. Y-o-Y Growth Projections by Type
   10.10. Market Attractiveness/Growth Potential Analysis
      10.10.1. By Country
      10.10.2. By Product Type
      10.10.3. By Application
      10.10.4. By Sales Channel
   10.11. Latin America Peptide Therapeutics Demand Share Forecast, 2019-2026

11. Europe Peptide Therapeutics Market Analysis and Forecast
   11.1. Introduction
      11.1.1. Basis Point Share (BPS) Analysis by Country
      11.1.2. Y-o-Y Growth Projections by Country
      11.1.3. Europe Average Pricing Analysis
   11.2. Europe Peptide Therapeutics Market Size and Volume Forecast by Country
      11.2.1. Germany
      11.2.2. France
      11.2.3. Italy
      11.2.4. U.K.
      11.2.5. Spain
      11.2.6. Russia
      11.2.7. Rest of Europe
   11.3. Absolute $ Opportunity Assessment by Country
   11.4. Europe Peptide Therapeutics Market Size and Volume Forecast by Application
      11.4.1. Cancer
      11.4.2. Metabolic Disorders
      11.4.3. Central Nervous System
      11.4.4. Other
      11.4.5. The key application of peptide therapeutics is into cancer mainly used for treating prostrate, pancreatic, ovarian, and breast cancer. and the consumption proportion is about 33.6% in 2017.
   11.5. Basis Point Share (BPS) Analysis by Application
   11.6. Y-o-Y Growth Projetions by Application
   11.7. Europe Peptide Therapeutics Market Size and Volume Forecast by Type
      11.7.1. Injection
      11.7.2. Oral
      11.7.3. Other
      11.7.4. The proportion of Injection in 2017 is about 74.2%, and the proportion is decreasing trend from 2013 to 2018.
   11.8. Basis Point Share (BPS) Analysis by Type
   11.9. Y-o-Y Growth Projections by Type
   11.10. Market Attractiveness/Growth Potential Analysis
      11.10.1. By Country
      11.10.2. By Product Type
      11.10.3. By Application
      11.10.4. By Sales Channel
   11.11. Europe Peptide Therapeutics Demand Share, 2019-2026

12. Asia Pacific Peptide Therapeutics Market Analysis and Forecast
   12.1. Introduction
      12.1.1. Basis Point Share (BPS) Analysis by Country
      12.1.2. Y-o-Y Growth Projections by Country
      12.1.3. Asia Pacific Average Pricing Analysis
   12.2. Asia Pacific Peptide Therapeutics Market Size and Volume Forecast by Country
      12.2.1. China
      12.2.2. Japan
      12.2.3. South Korea
      12.2.4. India
      12.2.5. Australia
      12.2.6. Rest of Asia Pacific (APAC)
   12.3. Absolute $ Opportunity Assessment by Country
   12.4. Asia Pacific Peptide Therapeutics Market Size and Volume Forecast by Application
      12.4.1. Cancer
      12.4.2. Metabolic Disorders
      12.4.3. Central Nervous System
      12.4.4. Other
      12.4.5. The key application of peptide therapeutics is into cancer mainly used for treating prostrate, pancreatic, ovarian, and breast cancer. and the consumption proportion is about 33.6% in 2017.
   12.5. Basis Point Share (BPS) Analysis by Application
   12.6. Y-o-Y Growth Projections by Application
   12.7. Asia Pacific Peptide Therapeutics Market Size and Volume Forecast by Type
      12.7.1. Injection
      12.7.2. Oral
      12.7.3. Other
      12.7.4. The proportion of Injection in 2017 is about 74.2%, and the proportion is decreasing trend from 2013 to 2018.
   12.8. Basis Point Share (BPS) Analysis by Type
   12.9. Y-o-Y Growth Projections by Type
   12.10. Market Attractiveness/Growth Potential Analysis
      12.10.1. By Country
      12.10.2. By Product Type
      12.10.3. By Application
      12.10.4. By Sales Channel
   12.11. Asia Pacific Peptide Therapeutics Demand Share, 2019-2026

13. Middle East & Africa Peptide Therapeutics Market Analysis and Forecast
   13.1. Introduction
      13.1.1. Basis Point Share (BPS) Analysis by Country
      13.1.2. Y-o-Y Growth Projections by Country
      13.1.3. Asia Pacific Average Pricing Analysis
   13.2. Middle East & Africa Peptide Therapeutics Market Size and Volume Forecast by Country
      13.2.1. Saudi Arabia
      13.2.2. South Africa
      13.2.3. UAE
      13.2.4. Rest of Middle East & Africa (MEA)
   13.3. Absolute $ Opportunity Assessment by Country
   13.4. Middle East & Africa Peptide Therapeutics Market Size and Volume Forecast by Application
      13.4.1. Cancer
      13.4.2. Metabolic Disorders
      13.4.3. Central Nervous System
      13.4.4. Other
      13.4.5. The key application of peptide therapeutics is into cancer mainly used for treating prostrate, pancreatic, ovarian, and breast cancer. and the consumption proportion is about 33.6% in 2017.
   13.5. Basis Point Share (BPS) Analysis by Application
   13.6. Y-o-Y Growth Projections by Application
   13.7. Middle East & Africa Peptide Therapeutics Market Size and Volume Forecast by Type
      13.7.1. Injection
      13.7.2. Oral
      13.7.3. Other
      13.7.4. The proportion of Injection in 2017 is about 74.2%, and the proportion is decreasing trend from 2013 to 2018.
   13.8. Basis Point Share (BPS) Analysis by Type
   13.9. Y-o-Y Growth Projections by Type
   13.10. Market Attractiveness/Growth Potential Analysis
      13.10.1. By Country
      13.10.2. By Product Type
      13.10.3. By Application
      13.10.4. By Sales Channel
   13.11. Middle East & Africa Peptide Therapeutics Demand Share, 2019-2026

14. Competition Landscape
   14.1. Global Peptide Therapeutics Market: Market Share Analysis
   14.2. Peptide Therapeutics Distributors and Customers
   14.3. Peptide Therapeutics Market: Competitive Dashboard
   14.4. Company Profiles (Details – Overview, Financials, Developments, Strategy) 
      14.4.1. Sanofi
         14.4.1.1. Overview
         14.4.1.2. Financials
         14.4.1.3. Developments
         14.4.1.4. Strategic Outlook
      14.4.2. Eli Lilly
         14.4.2.1. Overview
         14.4.2.2. Financials
         14.4.2.3. Developments
         14.4.2.4. Strategic Outlook
      14.4.3. Novo Nordisk
         14.4.3.1. Overview
         14.4.3.2. Financials
         14.4.3.3. Developments
         14.4.3.4. Strategic Outlook
      14.4.4. Takeda
         14.4.4.1. Overview
         14.4.4.2. Financials
         14.4.4.3. Developments
         14.4.4.4. Strategic Outlook
      14.4.5. Teva
         14.4.5.1. Overview
         14.4.5.2. Financials
         14.4.5.3. Developments
         14.4.5.4. Strategic Outlook
      14.4.6. Novartis
         14.4.6.1. Overview
         14.4.6.2. Financials
         14.4.6.3. Developments
         14.4.6.4. Strategic Outlook
      14.4.7. AstraZeneca
         14.4.7.1. Overview
         14.4.7.2. Financials
         14.4.7.3. Developments
         14.4.7.4. Strategic Outlook
      14.4.8. Ipsen
         14.4.8.1. Overview
         14.4.8.2. Financials
         14.4.8.3. Developments
         14.4.8.4. Strategic Outlook
      14.4.9. AbbVie
         14.4.9.1. Overview
         14.4.9.2. Financials
         14.4.9.3. Developments
         14.4.9.4. Strategic Outlook
      14.4.10. Allergan
         14.4.10.1. Overview
         14.4.10.2. Financials
         14.4.10.3. Developments
         14.4.10.4. Strategic Outlook
      14.4.11. Ferring
         14.4.11.1. Overview
         14.4.11.2. Financials
         14.4.11.3. Developments
         14.4.11.4. Strategic Outlook
      14.4.12. Merck
         14.4.12.1. Overview
         14.4.12.2. Financials
         14.4.12.3. Developments
         14.4.12.4. Strategic Outlook
      14.4.13. J & J
         14.4.13.1. Overview
         14.4.13.2. Financials
         14.4.13.3. Developments
         14.4.13.4. Strategic Outlook
      14.4.14. The Medicines
         14.4.14.1. Overview
         14.4.14.2. Financials
         14.4.14.3. Developments
         14.4.14.4. Strategic Outlook
      14.4.15. COMPANY 15
         14.4.15.1. Overview
         14.4.15.2. Financials
         14.4.15.3. Developments
         14.4.15.4. Strategic Outlook
      14.4.16. COMPANY 16
         14.4.16.1. Overview
         14.4.16.2. Financials
         14.4.16.3. Developments
         14.4.16.4. Strategic Outlook
      14.4.17. COMPANY 17
         14.4.17.1. Overview
         14.4.17.2. Financials
         14.4.17.3. Developments
         14.4.17.4. Strategic Outlook
      14.4.18. COMPANY 18
         14.4.18.1. Overview
         14.4.18.2. Financials
         14.4.18.3. Developments
         14.4.18.4. Strategic Outlook
      14.4.19. COMPANY 19
         14.4.19.1. Overview
         14.4.19.2. Financials
&n

Our Trusted Clients

Contact Us